

Glenmark - Recall of chlorzoxazone

- On April 25, 2022, <u>Glenmark announced</u> a consumer-level recall of some lots of <u>chlorzoxazone</u> tablets due to gaps in the microbiology quality control system.
 - Clinical Services will send notifications to members and their providers impacted by this recall.
 - The notifications provide information to help determine if the member's chlorzoxazone is being recalled.
 - Chlorzoxazone tablets that are not being recalled are available for patients to use.

Product Description	NDC#	Lot# (Expiration Date)
Chlorzoxazone 375 mg tablets	68462-724-01	29200035 (6/30/2022)
Chlorzoxazone 750 mg tablets	68462-725-01	29200036 (6/30/2022); 29200056 (9/30/2022); 29200070 (11/30/2022)

- Chlorzoxazone tablets are indicated as an adjunct to rest, physical therapy, and other measures
 for the relief of discomfort associated with acute, painful musculoskeletal conditions.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled chlorzoxazone.
- Contact Qualanex by phone at **1-888-504-2012** or by email at recall@qualanex.com for return information and for more information about the recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.